Nephros, Inc. reported significant financial improvements in its latest quarterly filing, with net revenues reaching $4.4 million for the three months ended June 30, 2025, a 36% increase from $3.3 million in the same period last year. For the first half of 2025, total net revenues were $9.3 million, up 37% from $6.8 million in the prior year. The company achieved a net income of $237,000 for the second quarter and $795,000 for the first half, contrasting with a net loss of $289,000 and $458,000 for the respective periods in 2024. This shift to profitability is attributed to increased sales in both programmatic and emergency response segments, driven by strong reorder activity and new active sites.
The company’s gross margin improved to 63% in the second quarter of 2025, up from 59% in the same quarter of 2024, primarily due to reduced shipping costs and adjustments in inventory reserves. Operating expenses also rose, with selling, general, and administrative expenses increasing by 13% to $2.2 million in the second quarter, largely due to higher sales commissions and stock-based compensation. Research and development expenses increased by 22% to $311,000, reflecting higher salary costs and bonus accruals.
Nephros has made strategic advancements, including the extension of its License and Supply Agreement with Medica S.p.A. until December 2028, which secures its supply of filtration products. The company continues to focus on expanding its market presence, particularly in the medical and commercial sectors, where its ultrafiltration products are gaining traction. As of June 30, 2025, Nephros reported a total of 10,600,604 shares outstanding, with stockholders' equity increasing to $9.6 million from $8.6 million at the end of 2024.
Operationally, Nephros has seen a positive trend in cash flow, generating $1.3 million from operating activities in the first half of 2025, compared to a cash outflow of $1.2 million in the same period of 2024. The company ended the quarter with cash and cash equivalents of $5.1 million, up from $3.8 million at the end of 2024. Nephros believes its current cash reserves are sufficient to support its operations for at least the next 12 months, although it acknowledges the potential need to reduce discretionary expenditures if market conditions do not meet expectations.
Looking ahead, Nephros aims to maintain its growth trajectory by focusing on sales expansion and cost management. The company is optimistic about its ability to capitalize on the increasing demand for high-quality water filtration solutions across various sectors, including healthcare and commercial markets. However, it remains cautious about potential challenges, including market acceptance and competitive pressures, which could impact future performance.
About NEPHROS INC
Nephros, Inc. develops and sells high-performance water filtration solutions for medical and commercial markets. Its products include ultrafilters for infection control in healthcare facilities and filters for improving water taste, odor, and contaminant reduction in food service, hospitality, and industrial settings. The company focuses on pathogen removal, regulatory compliance, and innovative filtration technologies to serve hospitals, dialysis centers, and commercial clients worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.